Clinical Trials Browser

Terminated × Neuroendocrine Tumors × Everolimus × Clear all

NCT02315625 2020-09-09

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Phase 2 Terminated

16 enrolled 15 charts

Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT03014297 2019-08-08

Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression

Phase 1 Terminated

Neuroendocrine Tumors

NCT01115803 2019-02-05

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Phase 1 Terminated

29 enrolled 19 charts

EndocrineGenitourinaryNETThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT01508104 2017-08-23

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

Phase 1 Terminated

CNSEndocrineNET

Brain Neoplasms, Glioblastoma, Neoplasms, Neuroendocrine Tumors

NCT01374451 2016-12-20

COOPERATE-2

Phase 2 Terminated

160 enrolled 17 charts

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT01628913 2016-04-07

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Phase 2 Terminated

62 enrolled 7 charts

Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors